Your session is about to expire
← Back to Search
Pirfenidone for Interstitial Lung Disease (PEARL Trial)
PEARL Trial Summary
This trial will study the effects of pirfenidone on patients with Hermansky-Pudlak Syndrome who also have interstitial lung disease.
- Interstitial Lung Disease
- Hermansky-Pudlak Syndrome
PEARL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPEARL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 4 trial • 105 Patients • NCT02579603PEARL Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still room for participation in this research endeavor?
"According to clinicaltrials.gov, this trial is not presently open for recruitment; having first been posted on December 1st 2019 and its last update being made on the 6th of that same month. Notwithstanding, there are currently 1677 other trials searching for participants."
Can individuals aged 55 and over participate in this research?
"Patients 18 to 75 years old can participate in this trial. For those outside of that age range, there are 398 studies for minors and 1,264 trials available for seniors."
Has this experiment been conducted before, or is it a novel endeavor?
"Currently, 11 cities and 5 countries are hosting 12 active trials involving Pirfenidone. Shanghai Genomics, Inc. initiated the first study in 2015 with 48 participants that eventually completed its Phase 2 clinical approval stage. Since then, an additional 44 experiments have been conducted to investigate the drug's efficacy further."
Can you provide an overview of precedent research concerning Pirfenidone?
"Currently, 12 clinical trials are looking into the effectiveness of Pirfenidone. One is in its final testing stage, Phase 3. Primarily based in Mayaguez and Pennsylvania, 14 centers are conducting these studies."
What is the enrollment count for this clinical research project?
"The recruitment period for this trial has ended. It was first publicized on December 1st 2019 and last revised on the 6th of that month. Currently, 1665 clinical trials related to diseases of the lungs are actively recruiting participants while 12 separate studies with Pirfenidone as an intervention remain open."
What potential risks accompany the use of Pirfenidone?
"Pirfenidone attained a score of 2, as there is evidence that it can be safe but no proof yet of its efficacy."
What criteria must an individual meet to be enrolled in this research?
"This clinical trial is seeking a cohort of 50 individuals, aged between 18 and 75 years old, with lung conditions. Furthermore, they must not have taken any cytotoxic or immunosuppressive drugs such as azathioprine, cyclophosphamide, cyclosporine etc., nor display any features suggestive of an alternative diagnosis like infection."
Share this study with friends
Copy Link
Messenger